Additional funding awarded to Maxim Biomedical, totaling approximately $4.4 million, will be used to accelerate the development of the FiarFly reader and COVID-19 & Flu A/B multiplex test and quickly prepare for clinical trials targeting this influenza season.
The FiarFly™ platform is a flexible, low-cost solution designed to bring diagnostic testing closer to the patient, providing lab-comparable performance in the home at an affordable cost. The pocket-sized, battery powered reader can produce results at a high sensitivity and at a cost comparable to visually read home-use tests. The platform allows for an expanded menu of tests on a single device and includes HIPAA-compliant connectivity for EMR results reporting.
“This funding reflects the confidence in the potential of our FiarFly™ platform and will enable us to advance our research and development efforts, bringing us one step closer to delivering a robust and reliable diagnostic tool that can make a meaningful difference in increasing access to highly accurate, rapid at-home testing solutions,” said Jonathan Maa, Chief Operating Officer at MaximBio.
The company was awarded the first round of RADx funding in May 2023.
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
READ ALSO
Biden Administration Announces $600M to Produce COVID Tests and Will Reopen Website to Order Them
The Biden administration announced it is providing $600 million in funding to produce new at-home COVID-19 tests and is restarting a website allowing Americans to again order up to four free tests per household — aiming to prevent possible shortages during a rise in coronavirus cases that has typically come during colder months. Twelve manufacturers that employ hundreds of people in seven states from California to Maryland have been awarded funding. HHS Secretary Xavier Becerra said that the “Biden-Harris Administration, in partnership with domestic manufacturers, has made great strides in addressing vulnerabilities in the U.S. supply chain by reducing our reliance on overseas manufacturing.” Associated Press (Sep 2023)
Rapid Antigen Diagnostics as Frontline Testing in the COVID-19 Pandemic
Rapid antigen diagnostics has played a significant role in the frontline of COVID-19 testing because of its convenience, low cost, and high accuracy. Herein, different types of recently innovated in-lab and commercial antigen diagnostic technologies with emphasis on the strengths and limitations of these technologies including the limit of detection, sensitivity, specificity, affordability, and usability are systematically reviewed. The perspectives of assay development are looked into. Small Science (July 2022)
The focus of this study is to compare the analytical performance of Halo (a small, highly accurate, consumer-friendly diagnostic reader paired with fluorescently labeled lateral flow assays and custom software for collection and reporting of results) against comparable tests that use either colloidal gold nanoparticles or fluorescence-based reporters in simulated nasal matrix and not in clinical samples. Frontiers in Public Health (April 2022)
Rapid Acceleration of Diagnostics: RADx (Tech + ATP)
Slidedeck from a virtual symposium featuring Bruce Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering covering the RADx program’s goals to expand COVID-19 testing technologies number, type and access; and to optimize performance and match community needs. (NIBIB). MaximBio, Luminostics, Ellume USA, Quidel, Qunaterix and others featured. OSTI (Oct 2020)